Table 1.
FDA Approved Targeted Therapies for Treatment of Soft Tissue Sarcoma.
| Medication | Mechanism of Action | Target | Sarcoma Type |
|---|---|---|---|
| Pazopanib | Tyrosine Kinase Inhibitor | VEGFR-1,-2,-3; PDGFR-α,-β; c-kit; FGFR-1,-3; c-fms | Non-adipocytic STS (12) |
| Pexidartinib | Tyrosine Kinase Inhibitor | CSF1R; c-kit | TGCT (23) |
| Imatinib | Tyrosine Kinase Inhibitor | PDGFR-β | Dermatofibrosarcoma Protuberans (28–30) |
| Crizotinib | Tyrosine Kinase Inhibitor | c-Met; ALK; ROS1 | IMT (33, 34) |
| Tazemetostat | EZH2 Inhibitor | EZH2 | Epithelioid Sarcoma (38) |
| nab-Sirolimus | mTOR inhibitor | mTOR Pathway | PEComa (45, 46) |
| Larotrectinib Entrectinib |
TRK inhibitor | TRK | TRK Fusion-Positive Tumors (50, 52–54) |
Vascular endothelial growth factor receptor (VEGFR); platelet derived growth factor receptor (PDGFR); stem cell growth factor receptor (c-kit); fibroblast growth factor receptor (FGFR); colony-stimulating factor-1 receptor (c-fms); tenosynovial giant cell tumor (TGCT); hepatocyte growth factor receptor (c-Met); anaplastic lymphoma kinase (ALK); inflammatory myofibroblastic tumor (IMT); mTOR (mammalian target of rapamycin); perivascular epithelioid tumor (PEComa).